New drug combo tested for aggressive, rare kidney cancer

NCT ID NCT03587662

Summary

This study is testing whether adding a new drug called ixazomib to two standard chemotherapy drugs works better for controlling an aggressive type of kidney cancer that has spread. It is for patients aged 12 and older whose cancer has progressed after other treatments and who have a specific genetic marker. The main goal is to see if the three-drug combination can shrink tumors or stop them from growing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.